BioSpace News Archive

Hudson Therapeutics, Inc. announced that Janice Marie McCourt has been appointed to co-Chief Executive Officer and a member of the Hudson Board of Directors, effective October 30, 2023.

Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.

Scinai Immunotherapeutics Ltd. announced receipt of a letter from the Nasdaq Stock Market dated November 1, 2023, regarding non-compliance with the requirement to maintain a minimum bid price of $1.00 per share.

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”) today announced promising updated preliminary translational data from the ongoing Phase 1 (AMPLIFY-201) study of its lead cancer vaccine candidate, ELI-002, in patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers, and new preclinical data on vaccine candidates, ELI-007 and ELI-008.

PTC Therapeutics, Inc. announced that on Nov. 1, 2023, the company approved non-statutory stock options to purchase an aggregate of 14,005 shares of its common stock and 19,125 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 21 new employees.

Aeglea BioTherapeutics, Inc. announced that Aeglea’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 729,600 shares of common stock of Aeglea to six non-executive employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended.

SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers at the Society for Immunotherapy of Cancer Annual Meeting 2023.

Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “Effects of aprocitentan on blood pressure lowering and proteinuria in patients with chronic kidney disease and resistant hypertension” by George Bakris, MD, at the American Society of Nephrology (ASN) Kidney Week 2023.

BioUtah today announced the winners of its 2023 Life Sciences Awards. Five awards will be presented during the 2023 Mayer Brown Utah Life Sciences Summit Nov. 9 at the Salt Palace, in Salt Lake City.

OncoNano Medicine, Inc. today presented positive preclinical data describing the effective delivery of interleukin-12 (IL-12) with the ON-BOARD™ platform technology at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).